- Home
- PMI vs NYXH Comparison
PMI vs NYXH Comparison
Compare PMI & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PMI | NYXH |
|---|---|---|
| Founded | 1981 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 202.7M | 190.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PMI | NYXH |
|---|---|---|
| Price | $0.95 | $3.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $11.25 |
| AVG Volume (30 Days) | ★ 159.2K | 53.1K |
| Earning Date | 03-25-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $214.32 |
| Revenue Next Year | N/A | $124.13 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.92 | $2.76 |
| 52 Week High | $13.68 | $8.64 |
Technical Indicators
Market Signals| Indicator | PMI | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 37.80 | 53.12 |
| Support Level | N/A | N/A |
| Resistance Level | $1.37 | $5.02 |
| Average True Range (ATR) | 0.10 | 0.17 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 6.89 | 95.32 |
Price Performance
Historical ComparisonAbout PMI Picard Medical Inc.
Picard Medical Inc operates through its wholly owned subsidiary, a medical technology company focused on developing, manufacturing, and commercializing an implantable Total Artificial Heart. It is engaged in designing, manufacturing, producing, supplying, marketing, and selling medical device products, including TAH. The TAH is an implantable system designed to assume the full function of a failed human heart in patients suffering from advanced heart failure.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.